Eliminateendotoxinsatthesource
- GeneticallymodifiedLPSdoesnottriggerendotoxicresponseinmammaliancells
- PlasmidyieldssimilartoDH10Bcells
- Idealformammaliantransfectionandproteinexpression
- Skipexpensive,timeconsumingendotoxinremovalsteps
- Frequentlyaskedquestions
- Introduction
- Genotypeinformation
- Whyendo-freeplasmidprepisnotthebestmethod
- PlasmidproductionwithClearColi
- Endotoxicity/LALlevels
- TransfectionandproteinexpressionfromClearColiPlasmids
- GrowthratesforClearColiK-12cells
- Usefulreferencearticles
- ClearColilicensinginformation
IntroductiontoClearColi®technology:
Isthereabetterwaytoeliminateendotoxincontamination?
Nowthereis.
Insteadofremovinglipopolysaccharide(LPS)contaminationfromyourproteinorplasmidDNApreparations,eliminatetheLPSatthesource. GeneticallymodifiedLPSfromanovel E.coli strainproducesfunctionallycleanrecombinantproteinsandplasmids. ClearColi®cellsarethefirstcommerciallyavailablecompetentcellswithamodifiedLPS(LipidIVA -seeFig.1)thatdoesnottriggertheendotoxicresponseinmammaliancells.ClearColicellslackoutermembraneagoNISTsforhTLR4/MD-2activation;therefore,activationofhTLR4/MD-2signallingbyClearColiisseveralordersofmagnitudelowercomparedwith E.coli wild-typecells,andplasmidDNApreparedfromClearColiisvirtuallyfreeofendotoxicactivity.AfterminimalpurificationfromClearColicells,proteinsorplasmids(whichmaystillcontain LipidIVA)canstillbeusedinmostapplicationswithoutelicitinganendotoxicresponse(seeEndotoxicityLALLevelsfordetails).
Figure1.TheLPSofanormalE.colicellcomparedtothegeneticallymodifiedLipidIVAfromClearColicells. InClearColi,theoligosaccharidechainhasbeendeleted,andtwoofthesixacylchainshavebeenremovedtodisabletheendotoxinsignal. |
ModificationstothegenotypeoftheClearColicellsconsistofsevenseparategenedeletions,therebyensuringthatthereisnochanceofgeneticreversionbacktowildtypeandproductionofnormalLPS. ThesemutationsresultinthedeletionoftheoligosaccharidechainfromtheLPS,makingiteasiertoremovetheresultinglipidIVA fromthedownstreamproduct. Moreimportantly,twoofthesixacylchainsaredeleted. ThesixacylchainsoftheLPSarethetriggerthatisrecognizedbytheToll-likereceptor4(TLR4)incomplexwithmyeloiddifferentiationfactor2(MD-2),causingactivationofNF-ƙBandproductionofproinflammatorycytokines. LipidIVA,whichcontainsonlyfouracylchains,isnotrecognizedbyTLR4andthusdoesnottriggertheendotoxicresponse(seeFig.2).
Fig.2.ComparisonofrelativeNF-κBinductioninHEK-BlueCellsusingpurifiedLPSfromaK-12 E.coli strainorfrompure,syntheticallymanufacturedLipidIVA. |
Backtotop▲
GenotypeInformation:
ClearColiK-12competentcellshavethefollowinggenotype:
F-,&lamBDa;- ΔendAΔrecAmsbA52frr181ΔgutQΔkdsDΔlpxLΔlpxMΔpagPΔlpxPΔeptA
Sevenspecificdeletionmutations(ΔgutQΔkdsDΔlpxLΔlpxMΔpagPΔlpxPΔeptA)encodethemodificationofLPStoLipidIVA,whileoneadditionalcompensatingmutation(msbA52)enablesthecellstomaintainviABIlityinthepresenceoftheLPSprecursorlipidIVA.
Backtotop▲
WhyEndo-freePlasmidPrepisnottheBestMethod
Topreventtoxicityincellstobetransfected,plasmidsproducedin E.colimustbeessentiallyfreeofendotoxin.However,efficienteliminationofendotoxinisachallengingtask,andendo-freeplasmidprepmethodsareexpensiveandtimeconsuming. ClearColiK-12cellsproduceplasmidDNAwithendotoxinlevelslessthanorequaltoplasmidspreppedfromstandardE.colicloninglinesandQiagen'sEndofreeMaxiPrepkits.
ClearColiK-12cellsallowuseofstandardplasmidprepinsteadofendo-freemethods:
- Savesupto90%inplasmidprepcosts
- Saves1hourormoreinpreptime
- Hightransfectionandproteinexpressionlevelswithoutconcernforendotoxincontamination
Backtotop▲
PlasmidProductionwithClearColiK-12Cells
ClearColiK-12cellsareendA-andrecA-forthehighestqualityplasmidproduction. PlasmidyieldsfromClearColiK-12cellsareequalorgreaterthanthoseobtainedfromnormalDH10Bcompetentcells. Table1comparesyieldsfrom1mLminiprepsforbothClearColiK-12andE.Cloni10G(equivalentOD'swereusedforbothpreps).
PlasmidDNAYield | |
ClearColiK-12 | 4.83µg/mL |
E.Cloni10G | 3.75µg/mL |
Backtotop▲
Endotoxicity/LALLevels
Limulus amebocyteassaytestingisanFDA-approvedmethodfordetectionofendotoxinsandthemostcommonassayused. Asshowninfigure3,astandardplasmidpurificationstepforDNAproducedfromClearColicellsresultsinLALresponselevelslessthan1%ofthatproducedbyplasmidsderivedfromstandardDH10Bcellsandstandardprepmethods. TheEUlevelsdetectedfromClearColiK-12derivedplasmidsarealsoequivalentorlowerthantothoseobtainedfromDH10BderivedplasmidspreparedwithQiagen'sEndofreeMaxiprepkits(datanotshown).
Fig.3Comparisonofpost-plasmidpurificationendotoxinunitsdetectedfromClearColiK-12(redbars)andDH10B(E.cloni10G,greybars)competentcells.PlasmidDNAfromClearColidemonstratessignificantreductioninEU/mgwithouttheneedforendotoxinfreeplasmidprepkits. |
ItshouldbenotedthattheresidualEUmeasurementsarelikelyduetothenon-specificnatureoftheLALassayunlessextraneousLPScontaminationfromothersourcesispresent.TheLALassayisactivatedsolelybythe4´-monophosphoryldiglucosaminebackboneofLPS. LALactivityisminimallyinfluencedbyacylationpatternofLPS,thekeydeterminantofendotoxicityineukaryoticcells. TheLALassayalsorecognizesawiderspectrumofLPS/lipidAvariantsthanthecentralcellularendotoxinsensorsystemofthehumanimmunecellsystem. Assuch,falsepositiveresultscanandwillresultduetothelackofspecificityoftheassay.
Alternativetoxicityassays,suchasthoseusingHEK-Bluecells(seeClearColi®BL21(DE3)cellsformoreinformation)suggestthateveninthepresenceofEUlevelsabovethreshholdsnormallytargetedbyresearchers,theactualimmunogeniceffectsfromClearColi-derivedproductsarenon-existent. Duetothenon-specificityoftheLALassaywhencombinedwithlipidIVA fromClearColi,itissuggestedthatresearchersconsideralternativemethodsofendotoxinmeasurement.
Backtotop▲
TransfectionandproteinexpressionfromClearColiPlasmids
Withtheoriginalsourceofendotoxineliminated,itisnowpossIBLetotransfectplasmidDNApreppedwithstandardmethodsdirectlyintohumanorothermammaliancelllineswithoutconcernforcellviability,alteredcellularresponsesorpoorproteinexpression. Toprovethis,aplasmid(pME-HA)containingageneencodingafluorescentproteinwasclonedintobothClearColiK-12andDH10BE.coli. TheplasmidfromClearColiwasthenisolatedviastandardQiagenMaxiprepkitmethod,whiletheplasmidfromDH10BwasisolatedusingQiagen'sEndofreeMaxiKit. TheresultingplasmidsweretransfectedintoHEK293Tcellsforproteinexpression(Figure4). Nodifferencesincellviabilityorproteinexpressionlevelshavebeenobservedwhenusinganon-endofreeplasmidprepmethodincombinationwithClearColi-derivedplasmids.
Figure4.ComparisonofexpressionofagreenfluorescentproteininHEK293TcellsfromClearColi-derivedplasmidsandstandardmaxiprep(left)vs.DH10B-derivedplasmidsandendofreemaxiprep(right).Theupperpanelsshowfluorescence;thelowerpanelsshowacombinedfluorescenceandbrightfieldimage. |
Backtotop▲
GrowthRatesforClearColiK-12Cells
ClearColiK-12cellsgrowatapproximately50%oftherateofnormalDH10Bcells(seeFig.5). Usersshouldexpecttoseeverysmallcoloniesforthefirst24hoursafterplatingtransformants. Lucigenrecommendsincubatingplatesfor32-40hoursbeforepickingcoloniesforfutureexperiments. Whengrowntosufficientdensities,ClearColiK-12cellsproducesimilarplasmidyieldsasnormalDH10Bcells.
Figure5.ComparisonofgrowthratesforClearColiK12ElectrocompetentCellsvs.E.cloni 10GELITEElectrocompetentcells. CellsweretransformedwithpME-HA-CometandinoculatedtoaninitialOD600 of~0.01in200mLofLBMillermediumandgrownat37°Cwithshakingat210rpm.TheOD600 ofthecultureswasrecordedeveryhalfhour. |
Backtotop▲
RelevantReferenceArticles:
- Teghanemt,etal,MolecularBasisofReducedPotencyofUnderacylatedEndotoxins,JImmunol,2005;175:4669-4676
- Mamat,etal,SingleaminoacidsubstitutionsineitherYhjDorMsbAconferviabilityto3-deoxy-D-manno-oct-2-ulosonicacid-depletedEscherichiacoli,MolecularMicroBIOLOGy,2008,67(3),633–648
- Meredith,etal,RedefiningtheRequisiteLipopolysaccharideStructureinEscherichiacoli,ACSChemicalBiology,2006,1(1),33-42
- Brandenburg,etal,TheExpressionofEndotoxicActivityintheLimulusTestasComparedtoCytokineProductioninImmuneCells,CurrentMedicinalChemistry,2009,16,2653-2660
- Gutsmann,etal.StructuralprerequisitesforendotoxicactivityintheLimulustestascomparedtocytokineproductioninmononuclearcells,InnateImmunity,2010,16(1),39-47
- BeomSeokPark1etal.,ThestructuralbasisoflipopolysacchariderecognitionbytheTLR4–MD-2complex,Nature458,1191-1195(30April2009)
Backtotop▲
ClearColiLicensingInformation:
ClearColiCompetentcellsaresubjecttoUSPatent8,303,964andotherUSandforeignpendingpatents.
LucigenCorporation("Lucigen")hasalicensefromResearchCorporationTechnologiestosellClearColicompetentcellstothird-partiesfornon-commercialresearchpurposesonly.Aseparatelicenseisrequiredforanycommercialuse.Formoreinformationabouttheuseofthisproductbycommercialentities,pleasereviewour fulllicensingpage.
Backtotop▲
ORDERINFORMATION
EachClearColi®K-12ElectocompetentCellKitcontains:ClearColiK-12ElectrocompetentCellsinDUOpackaging(2transformationspertube),RecoveryMedium,andpUC19PositiveControlPlasmid. Completeprotocolsareavailableonlineatwww.lucigen.com/manuals.
RecoveryMediumisalsoavailableseparately,catalog#80026-1.
Forresearchuseonly. Notforhumanordiagnosticuse.
Lucigen基因组编辑和工程面临许多挑战。为您的编辑实验获取可靠的试剂不应该是其中之一。无论您是在突破CRISPR技术的界限,在体内产生基因敲除或敲入还是在进行序列消化或鉴定的体外反应,您都需要可靠的工具和酶。依靠CRISPRcraft™获得质量,可靠性和稳定的性能。